title: Enhanced apoptosis of peripheral blood mononuclear cells in cardiac transplanted patients undergoing chronic immunosuppressive treatment.
abstract: Apoptosis plays a major role in tissue transplantation because intact T-cell-apoptosis pathways are required for the induction of tolerance to allografts. Moreover, immunosuppressive agents commonly used in clinical transplantation medicine promote lymphocyte apoptosis inhibiting the expression and production of cytokines involved in lymphocyte survival. The aim of our study was to evaluate peripheral blood mononuclear cells (PBMC) spontaneous apoptosis in patients undergoing chronic immunosuppressive treatment after cardiac transplantation. PBMC obtained from patients (n = 31) and controls matched for age and sex (n = 25) were cultured for 72 h and apoptosis was evaluated by quantification of fragmented DNA, staining with Hoechst 33258 dye and annexin V binding. We also investigated Fas expression and FasL mRNA expression as well as the ability of an IgM anti-Fas antibody to induce apoptosis. Finally, we evaluated IL2 production induced by PHA and the ability of IL2 to prevent apoptosis. In patients, PBMC underwent enhanced spontaneous apoptosis in comparison with controls. However, we could not find any difference between patients and normals as regards the expression of Fas and of FasL mRNA, even if the cross-linking of the Fas molecule induced apoptosis in PBMC from patients, whereas it failed to induce cell death in normals. We also found that IL2 production was significantly decreased in patients and that the addition of IL2 to the culture medium reduced PBMC spontaneous apoptosis. Our findings suggest that in cardiac transplanted patients PBMC undergo enhanced spontaneous apoptosis, which may contribute to prevent allograft rejection.
authors.affiliation: Istituto di Semeiotica Medica, Policlinico Le Scotte, Viale Bracci, University of Siena, 53100 Siena, Italy. cd28apo@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Di Renzo
authors.forename: P L
authors.initials: PL
authors.lastname: Capecchi
authors.forename: A
authors.initials: A
authors.lastname: Camurri
authors.forename: F
authors.initials: F
authors.lastname: Di Ciolla
authors.forename: M
authors.initials: M
authors.lastname: Maccherini
authors.forename: G
authors.initials: G
authors.lastname: Lisi
authors.forename: G
authors.initials: G
authors.lastname: Pompella
authors.forename: A L
authors.initials: AL
authors.lastname: Pasqui
authors.forename: A
authors.initials: A
authors.lastname: Auteri
authors.forename: M P
authors.initials: MP
authors.lastname: Abbracchio
authors.forename: F Laghi
authors.initials: FL
authors.lastname: Pasini
mesh_terms: D000328:Adult; D000368:Aged; D017209:Apoptosis / Q000187:drug effects*; D002470:Cell Survival; D053222:Fas Ligand Protein; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007376:Interleukin-2 / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000502:physiology; D008562:Membrane Glycoproteins / Q000502:physiology; D008875:Middle Aged; D012333:RNA, Messenger / Q000032:analysis; D019014:fas Receptor / Q000502:physiology
chemical_list: C505661:FASLG protein, human; D053222:Fas Ligand Protein; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D008562:Membrane Glycoproteins; D012333:RNA, Messenger; D019014:fas Receptor